BioMedAI · Agent Set 2
Autonomous Drug
Design Agents
ADDA takes validated targets from DBRA and applies generative AI to design, screen, and optimize candidate molecules — reasoning over structure-activity relationships, ADMET profiles, and synthesis feasibility.
In Active Development
70%
Projected faster drug design cycles
Stage 2
Follows DBRA target research output
Development Progress
Active development · Early access Q3 2025
DBRA — Live
ADDA — In Dev
ADDA is Stage 2 of the BioMedAI pipeline — it receives target validation outputs from DBRA and applies generative AI to molecule design.
Design Workflow
From Validated Target to Lead Candidate
ADDA agents orchestrate the full small molecule and biologics design loop with continuous optimization.
1. Target Input
Ingests validated targets from DBRA with structural constraints and binding site data.
2. Molecule Generation
Generative models propose novel candidate molecules optimized for binding affinity and selectivity.
3. ADMET Screening
Each candidate is scored for absorption, toxicity, metabolic stability, and bioavailability.
4. Lead Ranking
Top candidates are ranked by multi-parameter optimization and synthesis feasibility score.
Planned Capabilities
What ADDA Will Deliver
Generative Molecule Design
Novel small molecule and peptide generation using diffusion and transformer-based generative models trained on multi-billion compound libraries.
In Development
ADMET Prediction
Predict absorption, distribution, metabolism, excretion, and toxicity profiles for each candidate before any wet lab work.
In Development
Virtual Screening
High-throughput virtual screening of millions of compounds against validated targets with docking and ML-based affinity scoring.
In Development
SAR Analysis
Automated structure-activity relationship analysis to guide iterative lead optimization toward better potency and selectivity.
In Development
Antibody & Biologics Design
Extend generative design to antibody sequences, nanobodies, and other biologic modalities with developability scoring.
Planned
Synthesis Feasibility
Score and rank candidates by synthetic accessibility and retrosynthetic complexity — bridging computational and experimental chemistry.
Planned
In Development
Get Early Access to ADDA
We're working with select biopharma teams to co-develop ADDA's capabilities. If you have a drug design challenge, we'd like to hear from you.
Book a Discovery CallStart with DBRA While ADDA Launches
DBRA is live today. Get your target research automated now — and be first in line when ADDA ships.